Understanding PML Risk During Tysabri Treatment: What Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding the Legacy of Health Communication in Drug Safety

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). It's natural to wonder who is most at risk and what monitoring is needed. Decades of clinical experience have shaped our understanding of this drug-disease association, and this page covers the key risk factors that doctors use to guide closer monitoring.

Tysabri and PML: A Critical Drug-Disease Association

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The long-term outcome of PML in patients treated with Tysabri is generally poor, with the condition "usually lead[ing] to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This section examines the prognosis of Tysabri-associated PML, grounded in evidence from the drug's prescribing information. PML is an infection of the brain's white matter that typically occurs only in immunocompromised individuals. In Tysabri-treated patients, the infection arises because the drug alters immune surveillance in the central nervous system. The clinical presentation of PML can be subtle, with symptoms such as progressive weakness, visual changes, cognitive decline, or personality changes. Diagnosis often requires brain MRI and detection of JC virus DNA in cerebrospinal fluid. The prescribing information emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection is critical because the condition can progress rapidly.

Prognosis and Long-Term Outcomes of Tysabri-Associated PML

The prognosis for patients who develop PML while on Tysabri is guarded. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that PML can occur after varying durations of exposure. Long-term outcome data from these trials are limited, but the natural history of PML in immunocompromised populations suggests that survivors often have permanent neurological deficits. Several factors influence the risk of developing PML and, by extension, the prognosis. Three key risk factors are identified: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further increases that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prior immunosuppressant use compounds the risk. These factors should be weighed against the expected benefit when initiating or continuing Tysabri therapy.

Timeline, Monitoring, and Management of PML After Tysabri

The timeline between Tysabri exposure and PML onset is variable. PML has been reported during treatment and even after discontinuation. The prescribing information notes that "PML has been reported following discontinuation of TYSABRI in patients who did not have findings suggestive of PML at the time of discontinuation" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, monitoring should continue for at least six months after stopping the drug. This delayed onset complicates prognosis because the infection may be advanced by the time it is recognized. Management of PML in Tysabri-treated patients involves immediate withdrawal of the drug. The prescribing information instructs that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). There is no specific antiviral treatment for PML, so care focuses on supportive measures and immune reconstitution. In some cases, plasma exchange may be used to accelerate removal of Tysabri from the bloodstream, but this does not guarantee a favorable outcome. The prognosis remains poor even with intervention. The adequacy of warnings regarding Tysabri and PML is addressed through a restricted distribution program called the TOUCH Prescribing Program. This program is designed to ensure that patients are informed of the risks and that monitoring occurs. The boxed warning is prominently displayed, and the prescribing information details risk factors and monitoring requirements. However, despite these measures, PML continues to occur, and the long-term outcome for affected patients is often devastating.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for patients who develop PML after Tysabri treatment?

The long-term prognosis for Tysabri-associated PML is generally poor. According to the prescribing information, PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often have permanent neurological deficits.

What are the main risk factors for developing PML while on Tysabri?

Three key risk factors are identified: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.

Can PML occur after Tysabri is discontinued?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Monitoring should continue for at least six months after stopping the drug.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.